Notice to Readers: Information contained in our press releases should be considered accurate only as of the date of the release. Information in any press release may be superseded by more recent information we have disclosed in later press releases, filings with the Securities and Exchange Commission (“SEC”) or otherwise. Press releases may contain forward-looking statements based on the expectations of our management as of the date of the release. Actual results may materially differ based on several factors, including those described in the press releases and filings with the SEC.
11/10/2003 Biogen to Evaluate GlycoFi’s Protein Production Platform
11/10/2003 BIOGEN ANNOUNCES RESULTS OF PHASE II TRIALS WITH ADENTRI (TM) AT AMERICAN HEART ASSOCIATION MEETING
10/28/2003 Biogen Reports Third Quarter 2003 Financial Results
10/06/2003 IDEC PHARMACEUTICALS AND BIOGEN JOINT PROXY STATEMENT CLEARED BY SEC
10/01/2003 BIOGEN LICENSES ORAL PSORIASIS THERAPY FROM FUMAPHARM AG
09/22/2003 NEW STUDY SHOWS LONG-TERM EFFECT OF AVONEX® ON MS
08/07/2003 IDEC PHARMACEUTICALS AND BIOGEN ANNOUNCE U.S. FEDERAL TRADE COMMISSION CLEARANCE OF MERGER
08/01/2003 FDA APPROVES BIOGEN’S LARGE-SCALE MANUFACTURING FACILITY FOR COMMERCIAL PRODUCTION
07/24/2003 ANALYSIS OF ANTEGREN® PHASE III INDUCTION CLINICAL TRIAL IN CROHN’S DISEASE COMPLETED
07/24/2003 Biogen’s Second Quarter 2003 Reported EPS Increased 31 Percent to $0.38; Second Quarter Operating EPS Increased 26 Percent to $0.39 over Second Quarter 2002
06/23/2003 BIOGEN AND IDEC PHARMACEUTICALS ANNOUNCE MERGER TO CREATE A NEW BIOTECHNOLOGY INDUSTRY LEADER
06/23/2003 Biogen Reconfirms Full Year 2003 Revenue and EPS Guidance and Announces Revised Q2 EPS Outlook
06/20/2003 NEW DATA ON IM ADMINISTRATION SHOWS AMEVIVE® (alefacept) PROVIDES RELIEF FROM PSORIASIS FOR A MEDIAN OF 7 MONTHS
06/17/2003 GENENTECH AND BIOGEN ANNOUNCE AUTOIMMUNE COLLABORATION
06/13/2003 BIOGEN OBTAINS RIGHTS TO GENENTECH IMMUNOADHESON PATENTS
06/06/2003 Biogen Concludes its Participation in LFA-1 Antagonist Drug Development Program
06/06/2003 BIOGEN ANNUAL MEETING HIGHLIGHTS
05/30/2003 DATA ON PATIENTS TREATED WITH AVONEX® FOR UP TO EIGHT YEARS PRESENTED AT CONSORTIUM OF MULTIPLE SCLEROSIS CENTERS’ ANNUAL MEETING
05/29/2003 FDA APPROVES PREFILLED SYRINGE FOR AVONEX®
04/17/2003 Biogen Announces First Quarter 2003 Results
04/02/2003 Biogen Announces Improved Performance Expectations for First Quarter and Full Year 2003
03/27/2003 BIOGEN BREAKS GROUND ON LARGE-SCALE MANUFACTURING FACILITY IN DENMARK
02/20/2003 EUROPEAN APPROVAL OF AMEVIVE® DELAYED
02/14/2003 Biogen Reports Updated Fourth Quarter and Full Year 2002 Results for Berlex Settlement
02/11/2003 BIOGEN ELECTS BOSTON SCIENTIFIC CFO TO ITS BOARD OF DIRECTORS
02/07/2003 AVONEX® APPROVED BY FDA FOR PATIENTS WITH EARLY MULTIPLE SCLEROSIS
02/03/2003 U.S. Court of Appeals Issues Ruling on “McCormick” Patents Litigation
01/30/2003 IDEC Pharmaceuticals and Biogen Announce Oncology Collaboration
01/28/2003 BIOGEN ANNOUNCES FOURTH QUARTER AND FULL YEAR 2002 RESULTS
01/16/2003 Biogen Names Craig Eric Schneier, Ph.D. Executive Vice President, Human Resources
01/07/2003 Sunesis and Biogen to Discover Oral Therapeutics For Inflammatory and Immunological Diseases
01/07/2003 BIOGEN’S CEO PROFILES LONG TERM EARNINGS GROWTH POTENTIAL OF 20 PERCENT
01/02/2003 CLINICAL STUDY RESULTS PUBLISHED IN THE NEW ENGLAND JOURNAL OF MEDICINE SHOW PROMISING DATA ON ANTEGREN® (natalizumab) IN THE TREATMENT OF RELAPSING FORMS OF MULTIPLE SCLEROSIS
01/02/2003 ANTEGREN® (natalizumab) CLINICAL STUDY RESULTS PUBLISHED IN NEW ENGLAND JOURNAL OF MEDICINE SHOW PROMISING DATA ON DISEASE REMISSION AND QUALITY OF LIFE FOR PATIENTS WITH CROHN’S DISEASE